Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.
暂无分享,去创建一个
K. Do | H. Kantarjian | T. Manshouri | M. Keating | S. O'brien | F. Giles | M. Albitar | Xuemei Wang | H. Saffer | I. Jilani | D. Thomas
[1] P. Johnson,et al. Plasma nucleic acids in the diagnosis and management of malignant disease. , 2002, Clinical chemistry.
[2] I. Bernstein,et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.
[3] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[4] J. Vose,et al. A Phase II Multicenter Study of CAMPATH-1H Antibody in Previously Treated Patients with Nonbulky Non-Hodgkin's Lymphoma , 2001, Leukemia & lymphoma.
[5] J. Hainsworth. Rituximab as first-line systemic therapy for patients with low-grade lymphoma. , 2000, Seminars in oncology.
[6] M. Sliwkowski,et al. CD20: a gene in search of a function. , 2000, Seminars in oncology.
[7] S. O'brien,et al. High-dose rituximab therapy in chronic lymphocytic leukemia. , 2000, Seminars in oncology.
[8] P. Mclaughlin,et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. , 2000, Seminars in oncology.
[9] S. Pileri,et al. Efficacy of rituximab in hairy cell leukemia treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Byrd,et al. Campath-1H monoclonal antibody therapy , 2000, Current opinion in oncology.
[11] G. Hale,et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells , 2000, Bone Marrow Transplantation.
[12] A Kingman,et al. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] J. K. Hofmeister,et al. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. , 2000, Blood cells, molecules & diseases.
[14] Zhensheng Liu,et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. , 2000, Blood.
[15] M. Dimopoulos,et al. Waldenström's macroglobulinemia: clinical features, complications, and management. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Maloney. Preclinical and phase I and II trials of rituximab. , 1999, Seminars in oncology.
[17] L. Ginaldi,et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. , 1998, Journal of clinical pathology.
[18] P. Johnson,et al. The association between CD20 and Src-family Tyrosine kinases requires an additional factor. , 1998, Molecular Immunology.
[19] S. Robbins,et al. Rapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment* , 1998, The Journal of Biological Chemistry.
[20] F. Craig,et al. CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. , 1996, American journal of clinical pathology.
[21] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.
[22] G. Schieven,et al. Association of 75/80-kDa Phosphoproteins and the Tyrosine Kinases Lyn, Fyn, and Lck with the B Cell Molecule CD20 , 1995, The Journal of Biological Chemistry.
[23] H. Tilly,et al. Molecular cloning of a t(11; 14)(q13;q32) translocation breakpoint centromeric to the BCLI‐MTC , 1994, Genes, chromosomes & cancer.
[24] T. Tedder,et al. CD20: a regulator of cell-cycle progression of B lymphocytes. , 1994, Immunology today.
[25] G. L. Wilson,et al. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression. , 1994, Immunology today.
[26] M. Warzynski,et al. Low level CD20 expression on T cell malignancies. , 1994, Cytometry.
[27] E. Everett,et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia , 1992, American journal of hematology.
[28] G. Marti,et al. CD20 and CD5 Expression in B‐Chronic Lymphocytic Leukemia , 1992, Annals of the New York Academy of Sciences.
[29] P. Grambsch,et al. Martingale-based residuals for survival models , 1990 .
[30] T. Tedder,et al. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. , 1988, The Journal of biological chemistry.
[31] Richard A. Becker,et al. The New S Language , 1989 .
[32] J. Sedlák,et al. Monoclonal antibody directed to MHC class I antigen (Bra23/9): characterization and utilization for study of antigen expression in differentiation of U 937 cell line. , 1988, Neoplasma.
[33] E. Clark,et al. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. , 1985, Journal of immunology.
[34] W. Cleveland. Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .
[35] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[36] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[37] D.,et al. Regression Models and Life-Tables , 2022 .